ACC 23: BMAD Trial: μCor in Ambulatory Decompensated Heart Failure

ACC 23: BMAD Trial: μCor in Ambulatory Decompensated Heart Failure

ACC 23: BMAD Trial: μCor in Ambulatory Decompensated Heart Failure

We are joined on-site by Dr John Boehmer (Penn State Health, US) to discuss the findings of the BMAD-TX Trial, originally revealed at ACC 2023 (Zoll Medical Corporation). In this study, investigators aimed to assess the impact of a novel wearable sensor, the Microcor, (μCor™) in the management of heart failure. 266 patients with ambulatory decompensated heart failure were enrolled in the study.

The trial showed that managing heart failure using a threshold alert from the HFMS system results in 38% relative risk reduction in heart failure readmissions following hospitalisation.

Questions:
-What is the importance of this study?
-Could you please tell us about the μCor system?
-What was the patient population and study design?
-What are the main findings?
-How can these findings be put into clinical practice?
-What further research is needed?

Recorded on site at ACC 2023, New Orleans.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/?…

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications \u0026 creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCar…
Follow us on Twitter: https://twitter.com/radcliffeCARDIO


Content

0.51 -> My name is John Boehmer.
1.77 -> I'm a professor of medicine and surgery
3.81 -> at Penn State College of Medicine.
5.858 -> (pleasant music)
8.55 -> We're looking at ways of preventing re-hospitalization
12.06 -> following an admission for heart failure.
14.73 -> That's a major problem because the excess of 20% of patients
18.78 -> are readmitted within 30 days
20.91 -> and an excess of 40% by 90 days.
24.12 -> The main reason they're readmitted is for another diagnosis
27.78 -> of heart failure.
28.86 -> So we need a better way of managing those patients
31.32 -> during a high risk period
32.82 -> for a heart failure hospitalisation.
34.98 -> So MicroCor is a small adhesive patch.
38.61 -> It's a wearable device that uses low energy,
42.72 -> radiofrequency energy in order to get a measure
46.08 -> of lung fluid contact.
48.81 -> By doing that and combining it with data on heart rate
52.56 -> and respirations, it's able to provide information
55.86 -> to clinicians, which is then actionable.
58.71 -> Benefits of MicroCor and acute decompensated heart failure
62.28 -> trial is a two arm concurrent control clinical trial.
67.68 -> It's not a randomised controlled trial,
69.9 -> but had two arms, an intervention arm
72.21 -> and an observation arm going on concurrently.
75.48 -> We then compared the results
76.89 -> for heart failure hospitalisation between those two arms.
80.25 -> So the intervention arm where clinicians were able to see
84.15 -> the data as well as the patients able to see the data,
87.45 -> and the clinicians were able to act on it,
89.88 -> there was a 38% relative risk reduction in the risk
93.69 -> of a heart failure hospitalisation.
96.6 -> When we looked at the risk of a combined event
100.2 -> of heart failure hospitalisation,
101.76 -> and emergency department visit, or death
104.64 -> that was also reduced by 38%.
107.46 -> That is a 7% of patients total
112.71 -> who would've had a heart failure hospitalisation,
115.02 -> did not as a result of this intervention,
117.81 -> or a Number Needed to Treat of 14.
120.84 -> Well, we hope that this will be a new tool
122.88 -> that you will have for heart failure patients.
125.31 -> And one of the good things about it
127.92 -> is it's a wearable device.
129.72 -> It's not a long-term device that's implanted
132.57 -> and goes on and on.
134.01 -> This is just for the period of time where patients
137.01 -> are at increased risk.
138.39 -> Meaning that once you,
139.68 -> the patient is beyond that period of risk,
142.17 -> you can utilise it on a different patient.
144.57 -> So we hope that this will be utilised in practice now
148.05 -> and will be another tool that we have to monitor patients
151.95 -> through a high-risk period.
154.68 -> And further analyses are coming to help us
157.89 -> understand exactly how this work
160.29 -> and exactly what interventions work best.
163.05 -> So the next step is going to be delving
165.66 -> into the database more,
167.22 -> looking at what interventions were made by practitioners,
170.46 -> and then seeing which interventions had the most impact
173.52 -> on reducing heart failure hospitalizations,
176.22 -> and then coming up with the the best practices
178.98 -> based on those findings.
180.795 -> (pleasant music)

Source: https://www.youtube.com/watch?v=c0dZdIVhmJg